Two Years In US Accelerated Approval Withdrawals

Twenty accelerated approval indications have been voluntarily withdrawn by sponsors since December 2020, most coming as a result of the FDA cancer office’s push to rid labeling of ‘dangling’ and ‘delinquent’ indications that lack confirmation of clinical benefit.

red phones
The Oncology Center of Excellence has aggressively moved to clean up ‘dangling’ accelerated approval indications in the past two years. • Source: Shutterstock

Since December 2020, 20 indications that received US Food and Drug Administration accelerated approval have been voluntarily withdrawn by sponsors. Almost all were cancer drugs ensnared in the Oncology Center of Excellence’s push to clean up “dangling” and “delinquent” indications for which confirmatory trials have failed to verify clinical benefit or were never completed.

Below is a timeline of the withdrawal announcements, along with relevant related events, such as meetings of the Oncologic Drugs...

More from Pink Sheet Perspectives

More from Pink Sheet

US FDA’s ARIA Analysis Adds Earlier Scan To Biogen/Eisai Leqembi Label

 

Six deaths early in treatment inspired a new safety requirement for Biogen/Eisai’s Leqembi to promote early identification of patients affected by the well-known risk of amyloid-related imaging abnormalities with edema (ARIA-E).

COVID-19 Vaccines: Pfizer Arguments To Keep EUA Failed To Persuade US FDA’s Prasad

 
• By 

The CBER director rejected Pfizer’s assertions that pediatric dosing gaps, supply constraints and comparative mRNA content justify keeping the vaccine under emergency use authorization for younger children.

New US FDA AI Councils Will Focus On Internal, External Policy

 

The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.